SEARCH OHR


WHAT'S NEW?

Tradeshows 2010
OHR Kiosk
User Forum
Health-related News
Training Sessions
Most Recent Tracker

FEATURES

Find a Provider
Resources
Free Guides
Tracker Journal
Protocols/Algorithms
Job Postings
 

SOFTWARE SUPPORT

SYSTOC Software
Software Download
PDF-eXPLODE Software
User Forum
Contact Information
Training Sessions
E-mail Questions

ABOUT OHR

Our History
Mission Statement
Business Philosophy
Employment
What Clients Say
Staff Directory
Directions & Map

EXTERNAL LINKS

Ohio Employee Health Partnership
NAOHP/RYAN Associates
OHRHelp Meetings
OHR University
Microsoft Live Meeting
Adobe Reader
 

Occupational Health News & Analysis  

SAB Says PFOA is a Likely Carcinogen

[Posted 1/31/06] The Environmental Protection Agency’s (EPA) Science Advisory Board (SAB), which reviewed EPA’s Risk Assessment of Potential Human Health Effects Associated with Perfluorooctanoic Acid (PFOA), released a draft report stating that PFOA is “likely to be carcinogenic” based on EPA guidelines for carcinogen risk assessment. This is a stronger stance than EPA’s own assessment that there is “suggestive evidence of carcinogenicity, but not sufficient to assess human carcinogenic potential.” Several years ago, EPA started its investigation into PFOA and its salts because of concerns regarding its persistence in the environment and its presence in the blood of the general U.S. population at very low levels. Animal studies had shown that PFOA can cause developmental defects and had other adverse effects in laboratory animals.

The advisory board also recommended the further research on PFOA to investigate or accomplish the following:

  • Mode of action for liver tumor induction.

  • Include cancer endpoints, neurotoxicity, immunotoxicity, and hormonal effects in the risk assessment, aside from those already proposed by EPA.

  • Conduct occupational biomonitoring to identify potential human health effects.

  • Present a clear rationale on the choice of internal dose metrics to come up with the margins of exposure (MOE). The SAB suggested the use of benchmark dose (BMD) method for the calculation of No Observed Adverse Effect Level (NOAEL) or Lowest Observed Adverse Effect Level (LOAEL).

  • Retain the default uncertainty value for cross species extrapolation, since there is still a substantial gap in knowledge from animal and human biomonitoring studies.

  • Incorporate new data into its risk assessment as it becomes available.

PFOA is a synthetic compound also known as "C8." Companies like DuPont, maker of Teflon®, use PFOA to make fluoropolymers that have numerous important manufacturing and industrial applications. Commonly-used products made with fluoropolymers include non-stick cookware and breathable, all-weather clothing.

DuPont immediately responded to the SAB’s draft report and reiterated its position that the consumer products using PFOA and related chemicals are safe; there are no human health effects from exposure to PFOA, and that EPA’s current risk assessment that the chemical be classified as a “suggestive carcinogen” be retained. Although EPA is free to reject the SAB’s recommendations, it will probably take its suggestions seriously.

EPA, in its 2003 Federal Register publication, asked manufacturers of PFOA and companies using those chemicals in their products to do further research on PFOA through enforceable consent agreements, memoranda of understanding, and voluntary commitments. On January 25, 2006, EPA Administrator Johnson invited those companies to participate in a global stewardship program on PFOA and related chemicals. EPA is asking participating companies to reduce PFOA from emissions and product content by 95% no later than 2010, and to work toward eliminating PFOA from emissions and product content no later than 2015. DuPont has declared its willingness to work towards those goals.

Related Link:
EPA Info on PFOA
SAB Draft Report
Federal Register Environmental Documents
DuPont News Release

Return to News Summary Page:
Occupational Health News & Analysis

 

 

   

Home | Contact Information | E-mail Us | Terms of Use | Privacy Statement